Involvement of IRAKs and TRAFs in anti-β 2GPI/β 2GPI-induced tissue factor expression in THP-1 cells

Thrombosis and Haemostasis

Volumn 106, Issue 6, 2011, Pages 1158-1169

  Xu, Guoying ^a   Wen, Haiping ^a   Zhou, Hong ^a   Guo, Donglin ^a   Zhou, Fang ^a   Chen, Dongdong ^a   Xie, Hongxiang ^a   Wang, Ting ^a   Wang, Haibo ^a  

^a JIANGSU UNIVERSITY   (China)

Author keywords

2 glycoprotein I; Anti 2 glycoprotein i antibodies; IRAKs; Tissue factor; TRAFs

Indexed keywords

BETA2 GLYCOPROTEIN 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; MEMBRANE PROTEIN; MYELOID DIFFERENTIATION PROTEIN 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; UNCLASSIFIED DRUG;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOREGULATION; BINDING AFFINITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INNATE IMMUNITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UBIQUITINATION; UPREGULATION;

ANNEXIN A2; ANTIBODIES; ANTIGEN-ANTIBODY COMPLEX; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; CELL LINE, TUMOR; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; LEUPEPTINS; MONOCYTES; PACLITAXEL; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; THROMBOPLASTIN; TNF RECEPTOR-ASSOCIATED FACTOR 4; TNF RECEPTOR-ASSOCIATED FACTOR 6; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PEPTIDES AND PROTEINS;

EID: 82555193852     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-04-0229     Document Type: Article

References (50)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
2. Oosting JD, Derksen RH, Blokzijl L, et al. Antiphospholipid antibody positive sera enhance endothelial cell procoagulant activity--studies in a thrombosis model. Thromb Haemost 1992; 68: 278-284.
3. Amengual O, Atsumi T, Khamashta MA, et al. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79: 276-281.
4. Zhou H, Wolberg AS, Roubey RA. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004; 104: 2353-2358.
5. Lambrianides A, Carroll CJ, Pierangeli SS, et al. Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. J Immunol 2010; 184: 6622-6628.
6. Morrissey JH. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost 2001; 86: 66-74.
7. Owens AP 3rd, Mackman N. Tissue factor and thrombosis: The clot starts here. Thromb Haemost 2010; 104: 432-439.
8. Srinivasan R, Bogdanov VY. Alternatively spliced Tissue Factor: discovery, insights, clinical implications. Front Biosci 2011; 17: 3061-3071.
9. Ma K, Simantov R, Zhang JC, et al. High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000; 275: 15541-15548.
10. Sorice M, Longo A, Capozzi A, et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007; 56: 2687-2697.
11. Raschi E, Borghi MO, Grossi C, et al. Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. Lupus 2008; 17: 937-942.
12. Alard JE, Gaillard F, Daridon C, et al. TLR2 is one of the endothelial receptors for beta 2-glycoprotein I. J Immunol 2010; 185: 1550-1557.
13. Kobayashi K, Matsuura E, Liu Q, et al. A specific ligand for beta(2)-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J Lipid Res 2001; 42: 697-709.
14. Lutters BC, Derksen RH, Tekelenburg WL, et al. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'. J Biol Chem 2003; 278: 33831-33838.
15. Sikara MP, Routsias JG, Samiotaki M, et al. {beta}2 Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome. Blood 2010; 115: 713-723.
16. Zhou H, Wang H, Li N, et al. Annexin A2 mediates anti-beta 2 GPI/beta 2 GPIinduced tissue factor expression on monocytes. Int J Mol Med 2009; 24: 557-562.
17. Zhou H, Yan Y, Xu G, et al. Toll-like receptor (TLR)-4 mediates anti-ß(2) GPI/ß(2) GPI-induced tissue factor expression in THP-1 cells. Clin Exp Immunol 2011; 163: 189-198.
18. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine 2008; 42: 145-151.
19. Kobayashi M, Saitoh S, Tanimura N, et al. Regulatory roles for MD-2 and TLR4 in ligand-induced receptor clustering. J Immunol 2006; 176: 6211-6218.
20. Resman N, Vasl J, Oblak A, et al. Essential roles of hydrophobic residues in both MD-2 and toll-like receptor 4 in activation by endotoxin. J Biol Chem 2009; 284: 15052-15060.
21. Gao Y, Fang X, Tong Y, et al. TLR4-mediated MyD88-dependent signaling pathway is activated by cerebral ischemia-reperfusion in cortex in mice. Biomed Pharmacother 2009; 63: 442-450.
22. Brown J, Wang H, Hajishengallis GN, et al. TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk. J Dent Res 2011; 90: 417-427.
23. Martin M, Böl GF, Eriksson A, et al. Interleukin-1-induced activation of a protein kinase co-precipitating with the type I interleukin-1 receptor in T cells. Eur J Immunol 1994; 24: 1566-1571.
24. Croston GE, Cao Z, Goeddel DV. NF-kappa B activation by interleukin-1 (IL-1) requires an IL-1 receptor-associated protein kinase activity. J Biol Chem 1995; 270: 16514-16517.
25. Wesche H, Gao X, Li X, et al. IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. J Biol Chem 1999; 274: 19403-19410.
26. Kollewe C, Mackensen AC, Neumann D, et al. Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling. J Biol Chem 2004; 279: 5227-5236.
27. Kobayashi K, Hernandez LD, Galán JE, et al. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002; 110: 191-202.
28. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009; 27: 693-733.
29. Deng L, Wang C, Spencer E, et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000; 103: 351-361.
30. Boone DL, Turer EE, Lee EG, et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004; 5: 1052-1060.
31. Takeshita F, Ishii KJ, Kobiyama K, et al. TRAF4 acts as a silencer in TLR-mediated signaling through the association with TRAF6 and TRIF. Eur J Immunol 2005; 35: 2477-2485.
32. Di Simone N, Di Nicuolo F, D'Ippolito S, et al. Antiphospholipid antibodies affect human endometrial angiogenesis. Biol Reprod 2010; 83: 212-219.
33. Agar C, van Os GM, Mörgelin M, et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood 2010; 116: 1336-1343.
34. Zhang J, McCrae KR. Annexin A2 mediates endothelial cell activation by antiphospholipid/ anti-beta2 glycoprotein I antibodies. Blood 2005; 105: 1964-1969.
35. Zhou H, Ling S, Yu Y, et al. Involvement of annexin A2 in anti-beta2GPI /beta2GPI-induced tissue factor expression on monocytes. Cell Res 2007; 17: 737-739.
36. Romay-Penabad Z, Montiel-Manzano MG, Shilagard T, et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood 2009; 114: 3074-3083.
37. Janssens S, Beyaert R. Functional diversity and regulation of different interleukin- 1 receptor-associated kinase (IRAK) family members. Mol Cell 2003; 11: 293-302.
38. Raschi E, Testoni C, Bosisio D, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003; 101: 3495-3500.
39. Bohgaki M, Atsumi T, Yamashita Y, et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies. Int Immunol 2004; 16: 1633-1641.
40. Swisher JF, Burton N, Bacot SM, et al. Annexin A2 tetramer activates human and murine macrophages through TLR4. Blood 2010; 115: 549-558.
41. Zimmer SM, Liu J, Clayton JL, et al. Paclitaxel binding to human and murine MD-2. J Biol Chem 2008; 283: 27916-27926.
42. Resman N, Gradisar H, Vasl J, et al. Taxanes inhibit human TLR4 signaling by binding to MD-2. FEBS Lett 2008; 582: 3929-3934.
43. Eisenreich A, Celebi O, Goldin-Lang P, et al. Upregulation of tissue factor expression and thrombogenic activity in human aortic smooth muscle cells by irradiation, rapamycin and paclitaxel. Int Immunopharmacol 2008; 8: 307-311.
44. Noels H, Somers R, Liu H, et al. Auto-ubiquitination-induced degradation of MALT1-API2 prevents BCL10 destabilization in t(11;18)(q21;q21)-positive MALT lymphoma. PLoS One 2009; 4: e4822.
45. Jensen LE, Whitehead AS. Ubiquitin activated tumor necrosis factor receptor associated factor-6 (TRAF6) is recycled via deubiquitination. FEBS Lett 2003; 553: 190-194.
46. Opipari AW Jr, Hu HM, Yabkowitz R, et al. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J Biol Chem 1992; 267: 12424-12427.
47. Coornaert B, Carpentier I, Beyaert R. A20: central gatekeeper in inflammation and immunity. J Biol Chem 2009; 284: 8217-8221.
48. O'Reilly SM, Moynagh PN. Regulation of Toll-like receptor 4 signalling by A20 zinc finger protein. Biochem Biophys Res Commun 2003; 303: 586-593.
49. Heyninck K, Beyaert R. The cytokine-inducible zinc finger protein A20 inhibits IL-1-induced NF-kappaB activation at the level of TRAF6. FEBS Lett 1999; 442: 147-150.
50. Turer EE, Tavares RM, Mortier E, et al. Homeostatic MyD88-dependent signals cause lethal inflamMation in the absence of A20. J Exp Med 2008; 205: 451-464.